Back to Treatments

Treatment

Olaparib (PARP inhibitor)

1
Conditions
20
Trials
500
Participants
50%
Average Safety

Condition Evidence

Pancreatic cancer

20 trials · 500 participants

70% effectiveness · 50% safety
Olaparib (PARP inhibitor) | DFDA